Stockscreener 앱 받기
1.56%
시간 외 거래:
Amgen Inc 주식(AMGN)의 최신 뉴스
EMA: Amgen, Vifor Inflammatory Drug’s Benefits No Longer Outweigh Risks - MedCity News
Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh - TradingView
Amgen Continues To Perform (NASDAQ:AMGN) - Seeking Alpha
Amgen Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Enterprise value to EBIT forward of Amgen Inc. – NASDAQ:AMGN - TradingView
Amgen consensus steady ahead of next earnings, shares tracked against big pharma peers - Ad-hoc-news.de
Amgen Inc. Actuals & Estimates (NASDAQ:AMGN) - TradingView
EU regulator backs revoking Amgen's right to sell rare-disease drug - Reuters
European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked - WSJ
Amgen (AMGN) Faces EU Withdrawal Risk for Tavneos Due to Data In - GuruFocus
European Regulator Calls for Amgen's Tavneos to Have Authorization Revoked - marketscreener.com
EMA recommends revoking marketing authorisation for Amgen’s rare-disease drug - WKZO
Amgen faces EU withdrawal of rare-disorder therapy Tavneos - Seeking Alpha
Piper Sandler and Morgan Stanley Highlight Amgen (AMGN) on Pipeline Strength and Obesity Drug Potential - Insider Monkey
Amgen highlights obesity pipeline progress, shares track pharma peers - Ad-hoc-news.de
Amgen clears key resistance level, shares range between support and new highs - Ad-hoc-news.de
Price to earnings forward of Amgen Inc. – NASDAQ:AMGN - TradingView
Amgen reports new biosimilar data, shares in focus among healthcare peers - Ad-hoc-news.de
Amgen Inc. Actuals & Estimates (BMV:AMGN) - TradingView
Inside FDA’s Effort to Pull an Amgen Drug Over Alleged Data Manipulation - Bloomberg.com
Amgen’s Stock Is Down 10% From Its Highs: The $10 Billion Obesity Drug Bet That Could Define the Next Decade - TIKR.com
Amgen raises lower end of 2026 EPS target, shares stay in focus on NASDAQ - Ad-hoc-news.de
Amgen clears new 2026 high, shares extend biotech sector gains - Ad-hoc-news.de
Amgen dividend confirmed and capital plan detailed, shares under steady Wall Street scrutiny - Ad-hoc-news.de
AMGN Faces Market Scrutiny Over Data Integrity Issues - GuruFocus
Inside the FDA’s Effort to Pull an Amgen Drug Over Alleged Data Manipulation - Bloomberg.com
Amgen Inc. Stock 12‑Month Price Target Cut to $350.22 - TradingView
Willful Patent Verdict and Possible Treble Damages Could Be A Game Changer For Amgen (AMGN) - simplywall.st
IgG4-RD: From Diagnostic Delays to Collective Action in Rare Disease Care - Amgen
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen Inc. (AMGN) Price Target Raised to $303 After Q1 Model Update - Insider Monkey
Amgen lifts 2026 revenue outlook, shares trade in a tight NASDAQ range - Ad-hoc-news.de
Kyprolis from Amgen Inc.once-weekly regimen reshapes myeloma routine - Ad-hoc-news.de
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Globe and Mail
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Amgen (AMGN) Stock Could Be 2.1% Undervalued After Patent Verdict - simplywall.st
Are Biosimilars Becoming a Key Pillar of Amgen's Growth Story? - The Globe and Mail
(AMGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Update, Amgen faces Delaware patent verdict, shares under legal scrutiny - Ad-hoc-news.de
Amgen patent verdict reshapes risk picture, shares hold near recent highs - AD HOC NEWS
Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs Trade Ideas — BCBA:AMGN.CI - TradingView
Emerging Stars in Weight Loss: Regeneron and Amgen - Intellectia AI
Amgen faces Delaware patent verdict, shares under legal scrutiny - Ad-hoc-news.de
Tezspire from Amgen Inc.severe asthma biologic with shared AstraZeneca launch - AD HOC NEWS
Willful Patent Infringement Verdict Might Change The Case For Investing In Amgen (AMGN) - Yahoo Finance
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Amgen opens the week with upcoming catalysts, shares on Nasdaq - AD HOC NEWS
Amgen Inc. v. Amneal Pharm. LLC United States Court of Appeals of the Federal Circuit, 2020 945 F.3d 1368, 2020 - Sage Journals
What a Landmark Real-World Study Reveals About Thyroid Eye Disease - Amgen
Amgen StockWeekly outlook with earnings date and pipeline in view - AD HOC NEWS
Amgen France Names a New Communications Director - marketscreener.com
Why Amgen’s Repatha is quietly reshaping cholesterol therapy - AD HOC NEWS
Amgen Growth Drivers Surge 24 Percent as New Core Takes Over - HarianBasis.co
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026? - Yahoo Finance
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Amgen Rhode Island - Providence Business News
AMGN News | AMGEN INC (NASDAQ:AMGN) - ChartMill
Amgen Gives Greater Los Angeles Community an Experience to Remember at FIFA Fan Festival - Amgen
What If Amgen Stock's Patent Worries Are Hiding Its Real Growth Engine? - Yahoo Finance
What If Amgen Stock’s Patent Worries Are Hiding Its Real Growth Engine? - Trefis
Medtronic Ruling Supports IRS In Amgen Case, Tax Court Told - Law360
Amgen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Amgen's Diversified Business, Emerging Pipeline Drives Positive View, RBC Says - Moomoo
0.90%
자본화:
|
볼륨(24시간):